Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BSI-201 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| BSI-201 | EXPERIMENTAL | BSI-201 in combination with gemcitabine and carboplatin. |
| Pacitaxel/Carboplatin/Iniparib | EXPERIMENTAL | Participants will be administered pacitaxel, carboplatin and BSI-201 (Iniparib) in 21 day treatment cycles. Treatment will continue until disease progression or adverse effects prohibit further therapy. |
| Name | Type | Description |
|---|---|---|
| BSI-201 | DRUG | IV infusion, 5.6 mg/kg |
| paclitaxel | DRUG | Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days. |
| carboplatin | DRUG | Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days. |
| BSI-201 (Iniparib) | DRUG | BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days). |
Inclusion Criteria: * At least 18 years of age * Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma * Completion of only one previous course of chemotherapy which contained a platinum therapy, with sensitivity to that regimen. "Platinum-se...
Top 20 of 59 competitors
BSI-201 is an investigational small molecule being studied for use in oncology, specifically in glioblastoma, ovarian cancer, uterine carcinosarcoma, and other tumors. It has been evaluated in clinical trials for these conditions, though it remains in clinical development and is not approved.
BSI-201 is a poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, as indicated in the clinical trial title. It targets the PARP-1 enzyme, which is involved in DNA repair, making it a potential therapeutic approach for certain cancers.
BSI-201 is being developed by Sanofi, a global biopharmaceutical company traded on the stock exchange under the ticker SNY. Sanofi is responsible for the clinical development and potential commercialization of this investigational drug.
BSI-201 has completed Phase 1 and Phase 2 clinical trials. The most advanced studies were Phase 2, including a trial in platinum-resistant recurrent ovarian cancer. However, it is not approved and remains an investigational agent in clinical development.
BSI-201 has been studied in several completed trials, including NCT00298675, a Phase 1 dose escalation study in advanced solid tumors; NCT00422682, a Phase 1 combination study; NCT00687765, a Phase 1 study in malignant glioma; and NCT01033292, a Phase 2 study in ovarian cancer.
BSI-201 is also known as iniparib, a name that has been used in clinical research. It is a PARP-1 inhibitor that has been investigated for various cancers, including glioblastoma and ovarian cancer, though it is not approved.